New class of weight-loss drugs could reduce mortality: Swiss Re
GLP-1 drugs may reduce mortality by up to 6.4% in the US by 2045 Swiss Re’s optimistic scenario estimates GLP-1 drugs could lead to a reduction in cumulative all-cause mortality in the US general population of 6.4% over the next 20 years For the UK, Swiss Re’s optimistic scenario forecasts a 5.1% cumulative reduction in all-cause mortality in the general population, over the same time horizon Achieving the full potential of GLP-1 drugs is strongly dependent on availability, adoption rates, lifestyle and nutritional changes Monte Carlo (Sept. 17, 2025) – The widespread adoption of GLP-1 weight-loss drugs could reduce mortality rates in the coming decades, according to new Swiss Re research. Under optimistic scenarios, Swiss Re projects that GLP-1 medications could reduce all-cause mortality in the United States by as much as 6.4% by 2045. In the United Kingdom, the research suggests a reduction of over 5% is possible. Paul Murray, Swiss Re’s CEO Life & Health Reinsurance, says: “GLP-1 drugs hold significant promise to help us beat the obesity epidemic. Our research underscores that the full benefit will come from going beyond medication. As insurers, we are in a position to build partnerships, support policy and encourage people to...